{
  "id": "mcrc-egfr-main",
  "display_name": "mCRC RAS/BRAF WT (Main)",
  "cohort": "mCRC patients on EGFR inhibitors as 1L therapy â€” focus on commercial payers over 60%",
  "insight_type": "Revenue",
  "summary": "Analysis of 1,156 mCRC patients treated with EGFR inhibitors in first line reveals significant variation in commercial payer mix. The average commercial payer rate of 65% exceeds the peer benchmark of 60%, representing a positive revenue impact of $2.1M annually. Notable variations in biomarker testing rates and treatment duration suggest opportunities for further optimization.",
  "chart_data": [
    { "name": "Provider A", "value": 68 },
    { "name": "Provider B", "value": 65 },
    { "name": "Provider C", "value": 72 },
    { "name": "Provider D", "value": 63 },
    { "name": "Provider E", "value": 67 }
  ],
  "benchmark": 60,
  "table": [
    {
      "provider": "Provider A",
      "utilization_rate": "68%",
      "peer_avg": "65%",
      "revenue_gap": "$75,000"
    },
    {
      "provider": "Provider B",
      "utilization_rate": "65%",
      "peer_avg": "65%",
      "revenue_gap": "$0"
    },
    {
      "provider": "Provider C",
      "utilization_rate": "72%",
      "peer_avg": "65%",
      "revenue_gap": "$175,000"
    },
    {
      "provider": "Provider D",
      "utilization_rate": "63%",
      "peer_avg": "65%",
      "revenue_gap": "-$50,000"
    },
    {
      "provider": "Provider E",
      "utilization_rate": "67%",
      "peer_avg": "65%",
      "revenue_gap": "$50,000"
    }
  ],
  "suggestions": [
    "Optimize commercial payer authorization workflow",
    "Implement RAS testing quality improvement program",
    "Develop EGFR inhibitor duration tracking dashboard"
  ]
} 